Ação broncodilatadora do formoterol após 15 dias de tratamento em um paciente com Doença Pulmonar Obstrutiva Crônica

Chronic Obstructive Pulmonary Disease (COPD) is characterized by airflow limitation, causing increasing of the airway resistance and of the static pulmonary volumes, what is known as static hyperinflation. Consequently, COPD symptoms include dyspnea, typically aggravated by exercise, and sometimes c...

Full description

Bibliographic Details
Main Authors: Fernando Sergio S. Leitão Filho, Sérgio Roberto Nacif, Julio César Mendes de Oliveira, Luís Vicente Franco Oliveira
Format: Article
Language:Portuguese
Published: Universidade Nove de Julho 2009-01-01
Series:ConScientiae Saúde
Online Access:http://www.redalyc.org/articulo.oa?id=92912014017
id doaj-9adb9f4cf96f47829b11e102462fa321
record_format Article
spelling doaj-9adb9f4cf96f47829b11e102462fa3212020-11-24T21:48:29ZporUniversidade Nove de Julho ConScientiae Saúde1677-10281983-93242009-01-0182289294Ação broncodilatadora do formoterol após 15 dias de tratamento em um paciente com Doença Pulmonar Obstrutiva CrônicaFernando Sergio S. Leitão FilhoSérgio Roberto NacifJulio César Mendes de OliveiraLuís Vicente Franco OliveiraChronic Obstructive Pulmonary Disease (COPD) is characterized by airflow limitation, causing increasing of the airway resistance and of the static pulmonary volumes, what is known as static hyperinflation. Consequently, COPD symptoms include dyspnea, typically aggravated by exercise, and sometimes cough and sputum production. The treatment requires the use of bronchodilators, preferentially the inhalers, reducing the airway resistance and hyperinflation. Formoterol is one of the most used bronchodilators in COPD management, being considered a long-acting 2-adrenoceptor agonist. In this article, it is shown the extremely positive effect of this medication on pulmonary function in a COPD patient, just after 15 days of treatment.http://www.redalyc.org/articulo.oa?id=92912014017
collection DOAJ
language Portuguese
format Article
sources DOAJ
author Fernando Sergio S. Leitão Filho
Sérgio Roberto Nacif
Julio César Mendes de Oliveira
Luís Vicente Franco Oliveira
spellingShingle Fernando Sergio S. Leitão Filho
Sérgio Roberto Nacif
Julio César Mendes de Oliveira
Luís Vicente Franco Oliveira
Ação broncodilatadora do formoterol após 15 dias de tratamento em um paciente com Doença Pulmonar Obstrutiva Crônica
ConScientiae Saúde
author_facet Fernando Sergio S. Leitão Filho
Sérgio Roberto Nacif
Julio César Mendes de Oliveira
Luís Vicente Franco Oliveira
author_sort Fernando Sergio S. Leitão Filho
title Ação broncodilatadora do formoterol após 15 dias de tratamento em um paciente com Doença Pulmonar Obstrutiva Crônica
title_short Ação broncodilatadora do formoterol após 15 dias de tratamento em um paciente com Doença Pulmonar Obstrutiva Crônica
title_full Ação broncodilatadora do formoterol após 15 dias de tratamento em um paciente com Doença Pulmonar Obstrutiva Crônica
title_fullStr Ação broncodilatadora do formoterol após 15 dias de tratamento em um paciente com Doença Pulmonar Obstrutiva Crônica
title_full_unstemmed Ação broncodilatadora do formoterol após 15 dias de tratamento em um paciente com Doença Pulmonar Obstrutiva Crônica
title_sort ação broncodilatadora do formoterol após 15 dias de tratamento em um paciente com doença pulmonar obstrutiva crônica
publisher Universidade Nove de Julho
series ConScientiae Saúde
issn 1677-1028
1983-9324
publishDate 2009-01-01
description Chronic Obstructive Pulmonary Disease (COPD) is characterized by airflow limitation, causing increasing of the airway resistance and of the static pulmonary volumes, what is known as static hyperinflation. Consequently, COPD symptoms include dyspnea, typically aggravated by exercise, and sometimes cough and sputum production. The treatment requires the use of bronchodilators, preferentially the inhalers, reducing the airway resistance and hyperinflation. Formoterol is one of the most used bronchodilators in COPD management, being considered a long-acting 2-adrenoceptor agonist. In this article, it is shown the extremely positive effect of this medication on pulmonary function in a COPD patient, just after 15 days of treatment.
url http://www.redalyc.org/articulo.oa?id=92912014017
work_keys_str_mv AT fernandosergiosleitaofilho acaobroncodilatadoradoformoterolapos15diasdetratamentoemumpacientecomdoencapulmonarobstrutivacronica
AT sergiorobertonacif acaobroncodilatadoradoformoterolapos15diasdetratamentoemumpacientecomdoencapulmonarobstrutivacronica
AT juliocesarmendesdeoliveira acaobroncodilatadoradoformoterolapos15diasdetratamentoemumpacientecomdoencapulmonarobstrutivacronica
AT luisvicentefrancooliveira acaobroncodilatadoradoformoterolapos15diasdetratamentoemumpacientecomdoencapulmonarobstrutivacronica
_version_ 1725891897429327872